Home - Pistoia Alliance

Where life science

Collaborates

We are a global, not-for-profit members’ organization working to lower barriers to innovation in life science and healthcare R&D through pre-competitive collaboration.

Collaborate

Our ideas & interests>

Join the conversation

Our 2030 report is now available, hear our thoughts on what the challenges for the life science and healthcare industry will be in 2030. Get the report here

News

Almost One Third of Life Science Companies Set to Begin Quantum Computing Evaluation This Year

Boston, 14 July, 2020: New survey results from...

Pistoia Alliance and Mission: Cure win Bio-IT World 2020 Innovative Practices Award

Bio-IT World has announced the winners of the 2020...

AI CoE 2020 Drug repurposing datathon postponed

Our second drug repurposing datathon is dedicated to finding...

CAS and Pistoia Alliance partnering for Chemical Safety Library

CAS Makes Commitment to Enhance Laboratory Safety by Partnering...

View all News Items >

Latest Projects

Our projects transform R&D innovation through pre-competitive collaboration. We bring together the key constituents to identify the root causes that lead to R&D inefficiencies. We develop best practices and technology pilots to overcome common obstacles.

Project one: Digital health data in clinical studies

Bringing the industry together to define quality in study design and reporting for digital medicine by establishing consistency in the evidentiary base used to support clinical applications of digital medicine tools.

Why is this important?
What will the project achieve?
How will the project do this?
Find Out More >

To achieve broad adoption and positively impact health, digital medicine products require evidence to demonstrate that they are trustworthy. The quality and quantity of evidence required to deem a product fit-for-purpose are not agreed upon by industry, patient, or government stakeholders. Currently, there is no consensus on what constitutes “evidence” or what metrics should be used to distinguish high-quality evidence from low-quality evidence.

Defining quality in study design and reporting will drive the field of digital medicine towards maturity by establishing consistency in the evidentiary base used to support clinical applications of digital medicine tools. This will in turn allow trials to be run in a distributed fashion, collecting more critical data which will help produce better outcomes and more precision medicines.

The project will combine inputs from the key areas of digital medicine – patients, CROs, sponsors and technology companies to ensure that each stakeholders requirements are considered.

Project two: SEED Project

SEED will enable a FAIR aligned comprehensive semantic capture and translation of data across eLN providers at the point of entry. Output will be computer readable standard data, increasing capacity for provenance and attribute connection for insight and analysis

Why is this important?
What will the project achieve?
How will the project do this?
Find Out More >

Volumes of unstructured eLN content are exponentially growing
Most eLN content is free text, unstructured information and thus challenging to identify common concepts, to effectively search and extract deeper Insights
Retrospective data analysis and searching of generally unstructured content is a huge challenge
Data Workflows to/from eLNs can be relatively restricted in approach. Connectivity to Study Registration systems to enable Scientists to reuse such metadata through API to eLN are a must
Availability of persistent identifiers challenges the capability of making data to be digitally discoverable and hinders aggregation of data inter-applications
Valuable insights are hampered by unstructured content which prevents deeper data analysis thereby losing competitive advantage

Through collaboration and alignment across the pharma industry, the SEED project will create a standardized computer readable FAIR aligned data foundation.

A working prototype solution will be created to enable data discoverability/insights inter and intra eLN system.

Comprehensive Pharma/eLN provider/ Semantic Provider representation
Clear and aligned agreement across those representing
Extensive Requirement gathering
Phased usecases to prove the value of the approach
Pharma endorsement and agreement of an Aligned Need
eLN provider embracing and enabling the guidance from Pharma
Defined stage gates of delivery of the project

Project three: User Experience for Life Sciences

We are a community of practitioners from the pharmaceutical, healthcare, and software industries. We have launched the User Experience (UX) for Life Sciences (LS) project to enable business to adopt UX principles and methods as they develop scientific software. Our first deliverable will be a toolkit.

Why is this important?
What will the project achieve?
How will the project do this?
Find Out More >

UX is a powerful tool for supporting the creation of effective and usable interfaces. Whilst UX is relatively widespread, the full potential of UX is still to be realised in the life sciences. The goal of this project is to empower life science professionals to get the most from these UX resources.

This project aims to enable UX in the R&D life sciences through engagement with a wider audience including stakeholders such as senior management. Our vision is to communicate the value added by UX at all levels of our organisations.

The project has built a toolkit which focus’s on issues faced in developing digital products specifically for R&D in the life science and healthcare environments. The UXLS toolkit includes UX techniques, methods and business-critical metrics.

View all Projects >